{"nctId":"NCT02648204","briefTitle":"Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.","startDateStruct":{"date":"2016-01-06","type":"ACTUAL"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":1201,"armGroups":[{"label":"Semaglutide 0.5 mg/Week","type":"EXPERIMENTAL","interventionNames":["Drug: semaglutide"]},{"label":"Semaglutide 1.0 mg/Week","type":"EXPERIMENTAL","interventionNames":["Drug: semaglutide"]},{"label":"Dulaglutide 0.75 mg/Week","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dulaglutide"]},{"label":"Dulaglutide 1.5 mg/Week","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dulaglutide"]}],"interventions":[{"name":"semaglutide","otherNames":[]},{"name":"Dulaglutide","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria: - Male or female, age at least 18 years at the time of signing informed consent. - HbA1c (glycosylated haemoglobin) 7.0 - 10.5% (53 - 91 mmol/mol) (both inclusive) - Subjects on stable diabetes treatment with metformin (minimum of 1500 mg/day or maximal tolerated dose documented in the patient medical record) for 90 days prior to screening Exclusion Criteria: - Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice) - Any condition, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol - Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before screening. An exception is short-term insulin treatment for acute illness for a total of equal to or below 14 days - History of pancreatitis (acute or chronic) - Screening calcitonin equal to or above 50 ng/L - Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary Thyroid Carcinoma - Renal impairment defined as eGFR (electronic case report form) below 60 mL/min/1.73 m\\^2 as per CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) - Subjects presently classified as being in New York Heart Association Class IV - Planned coronary, carotid or peripheral artery revascularisation on the day of screening - Proliferative retinopathy or maculopathy requiring acute treatment - History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and in-situ carcinomas) - Anticipated initiation or change in concomitant medications (for more than 14 consecutive days or on a frequent basis) known to affect weight or glucose metabolism (e.g. orlistat, thyroid hormones, corticosteroids)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c","description":"Results are based on HbA1c data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on-treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.51","spread":"0.06"},{"groupId":"OG001","value":"-1.78","spread":"0.06"},{"groupId":"OG002","value":"-1.11","spread":"0.05"},{"groupId":"OG003","value":"-1.37","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (kg)","description":"Results are based on body weight data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.56","spread":"0.28"},{"groupId":"OG001","value":"-6.53","spread":"0.28"},{"groupId":"OG002","value":"-2.30","spread":"0.27"},{"groupId":"OG003","value":"-2.98","spread":"0.27"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose","description":"Results are based on fasting plasma glucose data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.18","spread":"0.12"},{"groupId":"OG001","value":"-2.83","spread":"0.12"},{"groupId":"OG002","value":"-1.87","spread":"0.12"},{"groupId":"OG003","value":"-2.25","spread":"0.12"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic and Diastolic Blood Pressure","description":"Results are based on systolic and diastolic blood pressure data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.57","spread":"0.48"},{"groupId":"OG001","value":"-2.05","spread":"0.49"},{"groupId":"OG002","value":"-0.35","spread":"0.47"},{"groupId":"OG003","value":"-0.03","spread":"0.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.44","spread":"0.76"},{"groupId":"OG001","value":"-4.88","spread":"0.77"},{"groupId":"OG002","value":"-2.16","spread":"0.75"},{"groupId":"OG003","value":"-2.86","spread":"0.75"}]}]}]},{"type":"SECONDARY","title":"Change in Overall Scores for Patient Reported Outcomes: Diabetes Treatment Satisfaction Questionnaire","description":"The questionnaire contains 8 items and evaluates subjects' diabetes treatment in terms of convenience, flexibility and general feelings towards treatment. The result presented is 'Treatment Satisfaction' summary score (sum of 6 of the 8 items). Response options: 6 (best case) to 0 (worst case). Total scores range: 0-36. Higher scores=higher satisfaction. Results are based on data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was period where subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This includes observations recorded at, or after the date of first dose of trial product and not after first occurrence of following: the end-date of the 'on-treatment' observation period or initiation of rescue medication","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.60","spread":"0.28"},{"groupId":"OG001","value":"4.55","spread":"0.29"},{"groupId":"OG002","value":"4.52","spread":"0.28"},{"groupId":"OG003","value":"4.65","spread":"0.28"}]}]}]},{"type":"SECONDARY","title":"HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists Target","description":"Percentage of subjects who achieved HbA1c target below or equal to 6.5% (48 mmol/mol) after 40 weeks of treatment. Results are based on data from on-treatment without rescue medication period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.2","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"34.1","spread":null},{"groupId":"OG003","value":"47.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.8","spread":null},{"groupId":"OG001","value":"33.3","spread":null},{"groupId":"OG002","value":"65.9","spread":null},{"groupId":"OG003","value":"52.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 7-point Self-measured Plasma Glucose (SMPG) Mean Profile","description":"SMPG values were recorded at 7 time-points: before and 90 minutes after start of breakfast, lunch, and dinner, and at bedtime. Reported results are mean profile from on-treatment without rescue medication observation period. The 'on-treatment' observation period was period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.43","spread":"0.10"},{"groupId":"OG001","value":"-2.95","spread":"0.10"},{"groupId":"OG002","value":"-1.99","spread":"0.10"},{"groupId":"OG003","value":"-2.32","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline 7-point Self-measured Plasma Glucose Increment","description":"SMPG values were recorded at 7 time-points: before and 90 minutes after start of breakfast, lunch, and dinner, and at bedtime. Reported results are plasma glucose incremental profile from on-treatment without rescue medication observation period. The 'on-treatment' observation period was period where subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes observations recorded at, or after date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.77","spread":"0.08"},{"groupId":"OG001","value":"-0.93","spread":"0.09"},{"groupId":"OG002","value":"-0.44","spread":"0.08"},{"groupId":"OG003","value":"-0.63","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Blood Lipids (Total Cholesterol)","description":"Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit. Change from baseline is presented in terms of ratio to baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"0.01"},{"groupId":"OG001","value":"0.97","spread":"0.01"},{"groupId":"OG002","value":"0.97","spread":"0.01"},{"groupId":"OG003","value":"0.99","spread":"0.01"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Blood Lipids (Low Density Lipoprotein [LDL] Cholesterol)","description":"Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit. Change from baseline is presented in terms of ratio to baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":"0.02"},{"groupId":"OG001","value":"1.00","spread":"0.02"},{"groupId":"OG002","value":"0.97","spread":"0.02"},{"groupId":"OG003","value":"1.01","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Blood Lipids (High Density Lipoprotein [HDL] Cholesterol)","description":"Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit. Change from baseline is presented in terms of ratio to baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"0.01"},{"groupId":"OG001","value":"1.01","spread":"0.01"},{"groupId":"OG002","value":"1.00","spread":"0.01"},{"groupId":"OG003","value":"1.02","spread":"0.01"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Blood Lipids (Triglycerides)","description":"Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit. Change from baseline is presented in terms of ratio to baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":"0.02"},{"groupId":"OG001","value":"0.86","spread":"0.02"},{"groupId":"OG002","value":"0.91","spread":"0.02"},{"groupId":"OG003","value":"0.90","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Change in Body Mass Index (BMI)","description":"Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.63","spread":"0.10"},{"groupId":"OG001","value":"-2.33","spread":"0.10"},{"groupId":"OG002","value":"-0.82","spread":"0.10"},{"groupId":"OG003","value":"-1.08","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference","description":"Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.27","spread":"0.34"},{"groupId":"OG001","value":"-5.20","spread":"0.34"},{"groupId":"OG002","value":"-2.36","spread":"0.33"},{"groupId":"OG003","value":"-2.93","spread":"0.33"}]}]}]},{"type":"SECONDARY","title":"Change in Short Form Health Survey (SF-36v2™)","description":"The questionnaire contains 36 items across 8 domains and 2 summary scores. Score range: 0 (worst score) to 100 (best score). Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was period where subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.21","spread":"0.40"},{"groupId":"OG001","value":"2.04","spread":"0.40"},{"groupId":"OG002","value":"1.93","spread":"0.39"},{"groupId":"OG003","value":"1.29","spread":"0.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.45","spread":"0.49"},{"groupId":"OG001","value":"1.23","spread":"0.49"},{"groupId":"OG002","value":"0.95","spread":"0.48"},{"groupId":"OG003","value":"1.08","spread":"0.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"0.44"},{"groupId":"OG001","value":"2.00","spread":"0.44"},{"groupId":"OG002","value":"2.17","spread":"0.43"},{"groupId":"OG003","value":"1.05","spread":"0.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.98","spread":"0.48"},{"groupId":"OG001","value":"2.03","spread":"0.48"},{"groupId":"OG002","value":"1.39","spread":"0.47"},{"groupId":"OG003","value":"0.82","spread":"0.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"0.52"},{"groupId":"OG001","value":"1.54","spread":"0.52"},{"groupId":"OG002","value":"1.69","spread":"0.51"},{"groupId":"OG003","value":"0.77","spread":"0.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.65","spread":"0.43"},{"groupId":"OG001","value":"2.52","spread":"0.43"},{"groupId":"OG002","value":"1.86","spread":"0.42"},{"groupId":"OG003","value":"2.73","spread":"0.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.23","spread":"0.50"},{"groupId":"OG001","value":"1.97","spread":"0.50"},{"groupId":"OG002","value":"2.14","spread":"0.49"},{"groupId":"OG003","value":"1.83","spread":"0.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.18","spread":"0.49"},{"groupId":"OG001","value":"0.83","spread":"0.49"},{"groupId":"OG002","value":"0.78","spread":"0.48"},{"groupId":"OG003","value":"0.63","spread":"0.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.11","spread":"0.57"},{"groupId":"OG001","value":"1.57","spread":"0.58"},{"groupId":"OG002","value":"1.04","spread":"0.56"},{"groupId":"OG003","value":"1.08","spread":"0.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.89","spread":"0.49"},{"groupId":"OG001","value":"1.65","spread":"0.49"},{"groupId":"OG002","value":"1.43","spread":"0.48"},{"groupId":"OG003","value":"0.96","spread":"0.48"}]}]}]},{"type":"SECONDARY","title":"Subjects Who After 40 Weeks Treatment Achieve (Yes/no) HbA1c <7.0% (53 mmol/Mol) American Diabetes Association (ADA) Target","description":"Percentage of subjects who achieved HbA1c target below or equal to \\<7.0% (53 mmol/mol) after 40 weeks of treatment. Results are based on data from on-treatment without rescue medication period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.4","spread":null},{"groupId":"OG001","value":"78.7","spread":null},{"groupId":"OG002","value":"52.2","spread":null},{"groupId":"OG003","value":"66.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.6","spread":null},{"groupId":"OG001","value":"21.3","spread":null},{"groupId":"OG002","value":"47.8","spread":null},{"groupId":"OG003","value":"33.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Who After 40 Weeks Treatment Achieve (Yes/no) Weight Loss ≥5%","description":"Percentage of subjects who achieved weight loss ≥5% after 40 weeks of treatment. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null},{"groupId":"OG001","value":"63.0","spread":null},{"groupId":"OG002","value":"22.7","spread":null},{"groupId":"OG003","value":"30.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.1","spread":null},{"groupId":"OG001","value":"37.0","spread":null},{"groupId":"OG002","value":"77.3","spread":null},{"groupId":"OG003","value":"69.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Who After 40 Weeks Treatment Achieve (Yes/no) Weight Loss ≥10%","description":"Percentage of subjects who achieved weight loss ≥10% after 40 weeks of treatment. Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null},{"groupId":"OG001","value":"26.7","spread":null},{"groupId":"OG002","value":"3.3","spread":null},{"groupId":"OG003","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null},{"groupId":"OG001","value":"73.3","spread":null},{"groupId":"OG002","value":"96.7","spread":null},{"groupId":"OG003","value":"92.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Who After 40 Weeks Treatment Achieve (Yes/no) HbA1c <7.0% (53 mmol/Mol) Without Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemia Episodes and no Weight Gain","description":"Percentage of subjects achieved (yes/no) HbA1c \\<7.0% (53 mmol/mol) without severe or BG confirmed symptomatic hypoglycaemia episodes and no weight gain after 40 weeks of treatment. Results are based on data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was period where subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was subset of 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.5","spread":null},{"groupId":"OG001","value":"74.0","spread":null},{"groupId":"OG002","value":"44.1","spread":null},{"groupId":"OG003","value":"58.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","spread":null},{"groupId":"OG001","value":"26.0","spread":null},{"groupId":"OG002","value":"55.9","spread":null},{"groupId":"OG003","value":"41.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Who After 40 Weeks Treatment Achieve (Yes/no) HbA1c Reduction ≥1%","description":"Percentage of subjects who achieved (yes/no) HbA1c reduction of ≥1% after 40 weeks of treatment. Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.4","spread":null},{"groupId":"OG001","value":"83.3","spread":null},{"groupId":"OG002","value":"53.8","spread":null},{"groupId":"OG003","value":"67.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.6","spread":null},{"groupId":"OG001","value":"16.7","spread":null},{"groupId":"OG002","value":"46.2","spread":null},{"groupId":"OG003","value":"32.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Who After 40 Weeks Treatment Achieve (Yes/no) Weight Loss ≥3%","description":"Percentage of subjects who achieved (yes/no) weight loss of ≥3% after 40 weeks of treatment. Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.5","spread":null},{"groupId":"OG001","value":"76.7","spread":null},{"groupId":"OG002","value":"36.5","spread":null},{"groupId":"OG003","value":"44.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","spread":null},{"groupId":"OG001","value":"23.3","spread":null},{"groupId":"OG002","value":"63.5","spread":null},{"groupId":"OG003","value":"55.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Who After 40 Weeks Treatment Achieve (Yes/no) HbA1c Reduction ≥1% and Weight Loss ≥3%","description":"Percentage of subjects who achieved (yes/no) HbA1c reduction ≥1% and weight loss ≥3% 40 weeks of treatment. Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.2","spread":null},{"groupId":"OG001","value":"68.3","spread":null},{"groupId":"OG002","value":"25.1","spread":null},{"groupId":"OG003","value":"34.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.8","spread":null},{"groupId":"OG001","value":"31.7","spread":null},{"groupId":"OG002","value":"74.9","spread":null},{"groupId":"OG003","value":"65.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Adverse Events (TEAEs)","description":"A TEAE was defined as an AE with onset in the 'on-treatment' period (information collected while subjects were considered as exposed to trial product). This corresponded to information collected until the follow-up (5 weeks after the last treatment including a visit window of +7 days).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"966","spread":null},{"groupId":"OG001","value":"1015","spread":null},{"groupId":"OG002","value":"802","spread":null},{"groupId":"OG003","value":"957","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemia Episodes","description":"A treatment emergent hypoglycaemic episode was defined as an episode with onset in the 'on-treatment' period (information collected while subjects were considered as exposed to trial product). This corresponded to information collected until the follow-up (5 weeks after the last treatment including a visit window of +7 days). Severe or BG-confirmed symptomatic hypoglycaemia was defined as an episode that was severe according to the American Diabetes Association classification or BG-confirmed by a plasma glucose value \\<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes","description":"Percentage of subjects with treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes. A treatment emergent hypoglycaemic episode was defined as an episode with onset in the 'on-treatment' period (information collected while subjects were considered as exposed to trial product). This corresponded to information collected until the follow-up (5 weeks after the last treatment including a visit window of +7 days). Severe or BG-confirmed symptomatic hypoglycaemia was defined as an episode that was severe according to the American Diabetes Association classification or BG-confirmed by a plasma glucose value \\<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"1.7","spread":null},{"groupId":"OG002","value":"1.0","spread":null},{"groupId":"OG003","value":"1.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Amylase","description":"Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit. Change from baseline is presented in terms of ratio to baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"0.02"},{"groupId":"OG001","value":"1.22","spread":"0.02"},{"groupId":"OG002","value":"1.16","spread":"0.02"},{"groupId":"OG003","value":"1.20","spread":"0.02"}]}]}]},{"type":"SECONDARY","title":"Change in Lipase","description":"Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit. Change from baseline is presented in terms of ratio to baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.22","spread":"0.04"},{"groupId":"OG001","value":"1.32","spread":"0.04"},{"groupId":"OG002","value":"1.23","spread":"0.04"},{"groupId":"OG003","value":"1.29","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"Change in Pulse Rate","description":"Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.09","spread":"0.51"},{"groupId":"OG001","value":"3.96","spread":"0.51"},{"groupId":"OG002","value":"1.56","spread":"0.49"},{"groupId":"OG003","value":"2.42","spread":"0.50"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":301},"commonTop":["Nausea","Diarrhoea","Vomiting","Decreased appetite","Headache"]}}}